Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phibro Animal Health (PAHC) Cash & Equivalents (2016 - 2025)

Phibro Animal Health has reported Cash & Equivalents over the past 13 years, most recently at $55.5 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $55.5 million for Q4 2025, down 17.28% from a year ago — trailing twelve months through Dec 2025 was $55.5 million (down 17.28% YoY), and the annual figure for FY2025 was $68.0 million, down 3.65%.
  • Cash & Equivalents for Q4 2025 was $55.5 million at Phibro Animal Health, down from $72.8 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for PAHC hit a ceiling of $76.3 million in Q3 2022 and a floor of $33.0 million in Q4 2023.
  • Median Cash & Equivalents over the past 5 years was $57.9 million (2025), compared with a mean of $57.2 million.
  • Biggest five-year swings in Cash & Equivalents: tumbled 51.81% in 2023 and later skyrocketed 103.44% in 2024.
  • Phibro Animal Health's Cash & Equivalents stood at $63.4 million in 2021, then rose by 7.95% to $68.4 million in 2022, then tumbled by 51.81% to $33.0 million in 2023, then skyrocketed by 103.44% to $67.1 million in 2024, then fell by 17.28% to $55.5 million in 2025.
  • The last three reported values for Cash & Equivalents were $55.5 million (Q4 2025), $72.8 million (Q3 2025), and $68.0 million (Q2 2025) per Business Quant data.